Catalyst

Slingshot members are tracking this event:

Flamel Technologies(FLML) - now Avadel Pharmaceuticals(AVDL) plans to begin pivotal studies for FT227 by mid 2016 - Discontinued

Source Link:
http://seekingalpha.com/article/3387765-flamel-technologies-flml-ceo-mike-anderson-on-q2-2015-results-earnings-call-transcript?page=3

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
FLML
50%
AVDL
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details we received feedback from the FDA regarding the clinical development pathway for FT227, an abuse-deterrent, extended-release, oral hydromorphone product using our proprietary Trigger Lock drug delivery platform.Following this guidance from FDA we will be conducting an in vivo alcohol interaction study during the third quarter of 2016, which should provide further confirmation of the robust abuse-deterrent capabilities of Trigger Lock. 
http://seekingalpha....
Management Comment Avadel is currently seeking to divest or license this product candidate in addition to the full Trigger Lock platform and has discontinued spending on this platform."
https://www.streetin...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Mar 28, 2017
Occurred Source:
https://www.streetinsider.com/SEC+Filings/Form+10-K+AVADEL+PHARMACEUTICALS+For%3A+Dec+31/12716155.html
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Ft227, Abuse Deterrent
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.